Live Breaking News & Updates on Hospital Fundaci|Page 2
Stay updated with breaking news from Hospital fundaci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ProChile Presents Healthtech Beyond Borders August 10-13 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
May 06, 2021 published at 7:30 AMglobenewswire PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial GlobeNewswire May 06, 2021 BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona. Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid. ....
(0) BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona. Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid. ....
6 may 2021 PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4 th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona. Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid. ....